Castle Biosciences (CSTL) Invested Capital (2018 - 2026)

Castle Biosciences has disclosed Invested Capital across 9 years of filings, most recently posting $483.0 million for Q2 2026.

• In Q2 2026, Invested Capital rose 3.35% year-over-year to $483.0 million; the TTM figure through Jun 2026 stood at $483.0 million (up 3.35% YoY), while the FY2025 annual figure was $481.3 million, up 3.26% from the prior year.
• Invested Capital came in at $483.0 million for Q2 2026 at Castle Biosciences, up from $473.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $483.0 million in Q2 2026 to a low of $385.1 million in Q1 2023.
• Average Invested Capital over 5 years is $445.5 million, with a median of $451.4 million recorded in 2025.
• Year-over-year, Invested Capital fell 7.9% in 2023 and gained 19.13% in 2024.
• Over 5 years, Invested Capital stood at $418.2 million in 2022, then retreated by 6.44% to $391.3 million in 2023, then gained by 19.13% to $466.1 million in 2024, then rose by 3.26% to $481.3 million in 2025, then gained by 0.35% to $483.0 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $483.0 million in Q2 2026, $473.1 million in Q1 2026, and $481.3 million in Q4 2025.